I think the FDA priority review is a milestone, but still the ultimate decider is the approval in 6 month.
however, given the valuation, I think the market could overlook the positive validation from priority review. Because it could potentially mean other MSB products can achieve similar special status, affirming their life saving advantages
I'm Confused, page-4
-
- There are more pages in this discussion • 14 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
99.8¢ |
Change
0.003(0.25%) |
Mkt cap ! $1.138B | |||
| Open | High | Low | Value | Volume |
| 99.0¢ | $1.03 | 98.5¢ | $1.696M | 1.698M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 19 | 11285 | 99.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.00 | 27795 | 13 |
View Market Depth
| Last trade - 13.45pm 05/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |